News

404

International Growth Leaders Event June 24, 2025

International Growth Leaders Event June 24, 2025

Dr. Theresa Visarius of Immunophotonics Switzerland (IPS Biopharma AG) served as a keynote speaker and panelist at the International Growth Leaders, Driving Global Success event of the Swiss Association of MBAs, held June 24th in Switzerland. This event brought together global leaders to explore strategies for market expansion and offered valuable insights into navigating cross-border...

BIO International Convention June 16-19, 2025

Lu Alleruzzo (CEO) and Robert Arch (SVP of Corporate Development) at Immunophotonics, Inc. will be attending the BIO International Convention in Boston from June 16-19, 2025.  This event is among the largest biotechnology events for global industry leaders and investors. They are looking forward to connecting with biotech leaders, investors, and partners who share a passion for transforming patient outcomes...

Volunteering at World Wide Technology American Cancer Society Hope Lodge

The Immunophotonics team had the privilege of volunteering at the World Wide Technology American Cancer Society Hope Lodge in St. Louis, Missouri. We spent part of the evening baking cookies and brownies for cancer patients and their caregivers. This experience was deeply meaningful for all of us. We are incredibly grateful to the patients and...

Immunophotonics Event May 7th

A Heartfelt Thank You to Our Event Attendees. We extend our gratitude to everyone who attended our event last night. Your support means the world to us! We would also like to express our appreciation to our esteemed guest speakers: Prof. Louis Liou, Prof. Constantinos “Costi” Sofocleous, and Prof. Wei R. Chen, who generously took...

Swiss Biotech Day May 5-6, 2025

Immunophotonics is thrilled to share that Dr. Theresa Visarius from Immunophotonics Switzerland (IPS Biopharma AG) will be presenting at the Swiss Biotech Days 2025 in Basel, Switzerland, on May 6th. Join her in room Montreal at 15:45 in the Clinical Stage Companies Session to hear about our Tumor-Specific Immune Activation to Prevent Cancer Recurrence.

LSX World Congress Europe April 28–30, 2025

Immunophotonics is excited to share that Dr. Theresa Visarius, VP Business Development will be attending the LSX World Congress Europe in London, April 28-30. This is a great opportunity to meet Theresa personally and hear how our phase 2 clinical stage asset, IP-001, provides a unique solution to combat solid tumor cancers and prevent their...

AACR April 25-30, 2025

Tomas Hode, PhD, CIO & President will be attending the American Association of Cancer Research (AACR) annual meeting April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL.  This pivotal event brings together scientists, clinicians, healthcare professionals, survivors, patients, and advocated to share and discuss the latest advancements in innovative cancer research and...

Jacqueline Hess Joins Immunophotonics Board of Directors

Immunophotonics, Inc. has strengthened its leadership team with the appointment of Jacqueline Hess to its Board of Directors.  With over 30 years of experience in leading and advising heavily regulated businesses that leverage the trans-Atlantic corridor as part of their growth journey, Ms. Hess joins an already-robust slate of directors currently serving on the Board...

ECIO April 13–16, 2025

Diane Beatty, PhD, VP of Regulatory and Clinical Affairs, and Kelly Porterfield, Director of Clinical Operations, will be participating in the European Conference on Interventional Oncology (ECIO) in Rotterdam, Netherlands, from April 13 to 16.  They will be accompanied by Lu Alleruzzo, CEO, and Tomas Hode, PhD, CIO & President. This prestigious event is one...

University of Oklahoma Entrepreneurial Seminar Series April 4, 2025

Lu Alleruzzo, CEO and Tomas Hode, PhD, President & CIO were honored to be invited to present at the Entrepreneurial Seminar Series hosted by The University of Oklahoma Stephenson School of Biomedical Engineering. Their presentation titled “Development and Commercialization of a Novel Immunostimulant in Combination with Local Ablation for the Treatment of Metastatic Cancers” will...

Scroll to top